Non-Hodgkin lymphoma and chronic lymphocytic leukemia research hub
4 indexed studies · 0 currently recruiting
- ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
This study is looking at a new combination of two medicines, JNJ-67856633 and ibrutinib, for people with certain types of blood cancer like non-Hodgkin lymphoma and chronic lymphocytic leukaemia. It's an early-stage study to see if the combination is safe and how well it works.
France · Poland - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
This study is looking at a new medicine called JNJ-64264681 for people with non-Hodgkin lymphoma and chronic lymphocytic leukaemia. It's a very early-stage study to check if the medicine is safe, how it moves through the body, and what it does in the body.
Poland - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
This study is looking at a new combination of two medicines for people with non-Hodgkin lymphoma and chronic lymphocytic leukaemia. It will check how safe they are, what they do in the body, and how well they work together.
Poland · Belgium - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL
This early-stage study is testing a new medicine called JNJ-67856633 in people with specific blood cancers: Non-Hodgkin lymphoma and chronic lymphocytic leukemia. The main goal is to see if the medicine is safe, how it moves through the body, and what effects it has.
France · Greece